Harvard Bioscience, Inc. (NASDAQ:HBIO) CFO Robert E. Gagnon sold 97,087 shares of Harvard Bioscience stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $4.62, for a total transaction of $448,541.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Harvard Bioscience, Inc. (NASDAQ HBIO) traded up $0.20 during mid-day trading on Monday, reaching $4.80. 144,131 shares of the company’s stock were exchanged, compared to its average volume of 167,103. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40. Harvard Bioscience, Inc. has a 1 year low of $2.25 and a 1 year high of $5.20. The company has a market capitalization of $160.45, a PE ratio of -235.00 and a beta of 1.32.
Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, March 1st. The medical instruments supplier reported $0.05 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.05. The firm had revenue of $27.46 million during the quarter, compared to analysts’ expectations of $26.60 million. Harvard Bioscience had a negative net margin of 0.85% and a positive return on equity of 2.38%. research analysts expect that Harvard Bioscience, Inc. will post 0.11 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of Harvard Bioscience by 2,013.7% in the fourth quarter. Wells Fargo & Company MN now owns 32,446 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 30,911 shares during the period. New York State Common Retirement Fund bought a new stake in shares of Harvard Bioscience in the third quarter valued at about $321,000. Northern Trust Corp boosted its position in shares of Harvard Bioscience by 5.2% in the second quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after acquiring an additional 4,260 shares during the period. Algert Global LLC boosted its position in shares of Harvard Bioscience by 31.0% in the third quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after acquiring an additional 35,276 shares during the period. Finally, AXA boosted its position in shares of Harvard Bioscience by 16.7% in the fourth quarter. AXA now owns 167,500 shares of the medical instruments supplier’s stock valued at $553,000 after acquiring an additional 24,000 shares during the period. 63.54% of the stock is owned by institutional investors.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.